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Isolated elevation of cardiac troponin is associated with better pro-
gnosis of non-ST segment elevation myocardial infarction
Filipa Cordeiro, S.Leao, P.Magalhaes, A.Baptista, A.Ferreira, Ps Mateus,
Ji Moreira
Centro Hospitalar de Tras-os-Montes e Alto Douro, Cardiology, Vila
Real, Portugal
Purpose: We sought to evaluate the effect of isolated elevation of cTn on
short-term outcomes of NSTE-MI
Methods: From Oct 2010 to Oct 2013, 3799 patients with NSTE-MI were
enrolled on a national multicenter registry. These patients were divided in
2 groups: BM+: elevation of cTn and other biomarkers of myocardial injury
(n=2445); BM-: elevation of cTn without rise in the other biomarkers
(n=948).The endpoints included in-hospital all-cause mortality and a com-
posite endpoint of death, re-infarction, heart failure (Killip class >2) and
resuscitated cardiac arrest during hospitalization. Logistic regression model-
ling was used to compute adjusted odds ratio of death and of the composite
endpoint. 
Results: The BM- patients were younger (66±12 vs. 68±13, p<0.001),
more likely to have undergone previous percutaneous coronary intervention
(18.6% vs. 15.1%, p=0.013) and had higher baseline values of low-density
lipoprotein-cholesterol (114±39 vs. 111±39, p=0.03). Multivessel disease was
more frequent in BM+ patients (58.1% vs. 53.5%, p=0.026). Patients with
BM- had lower incidence of heart failure (8.4% vs. 20.8% with Killip class
>1, p<0.001), left ventricular dysfunction (10.4% vs. 18.4% with left ventri-
cular ejection fraction <40%, p<0.001) and the composite endpoint (5.1% vs.
11.9%, p<0.001). In-hospital all-cause mortality was more common in those
BM+ (3.0% vs. 0.7%, p<0.001). In a multivariable model, no significant asso-
ciation was found between BM- and in-hospital all-cause mortality (OR:
0.568, 95% CI: 0.127-2.549, p=0.461). Isolated elevation of cTn was associ-
ated with lower incidence of the composite endpoint (OR: 0.474, 95% CI:
0.312-0.722, p=0.001).
Conclusion: In this observational nationwide study, patients with iso-
lated cTn elevation showed a better short-term prognosis than those with
elevation of all biomarkers of myocardial injury. The higher sensitivity of
cTn might be associated with less myocardial damage and therefore fewer
complications. 
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Uselessness of high-sensitivity cardiac troponins to improve diagnostic
accuracy of dobutamine stress echocardiography in high-risk diabetic
patients
Falah Aboukhoudir (1), Sofiene Rekik (2), Imed Aboukhoudir (1), Michel
Pansieri (1)
(1) CH Avignon, Cardiologie, Avignon, France – (2) CH Antibes, Cardio-
logie, Antibes, France
Background and aim: Dobutamine stress echocardiography (DSE) is a
well-established noninvasive stress modality for the detection and evaluation
of coronary artery disease in diabetic patients. High-sensitivity cardiac tro-
ponin T recently emerged as a highly sensitive dosage for the detection of
ischemia. The aim of the study was to examine whether high-sensitivity car-
diac troponin T may improve the diagnostic accuracy of silent ischemia by
DSE in high-risk diabetic patients.
Methods and results: 21 patients with long-standing (>10 years) and/or
complicated type II DM but no established CAD were included. In addition to
DSE, venous blood samples for measurement of hs-cTnT and were collected
prior to DSE, 6H and 24 hours after the test. Troponins were deemed positive
if >1.5 upper limit for normality. Patients with positive troponins underwent
coronary angiography or CT scan regardless of the result of DSE. Among the
21 patients, 7 had positive troponins measured 6 hours after stress, (mean peak
troponin=44.5). DSE were negative in all of them. Mean age was 64 years
significantly higher than patients with negative troponins. No differences were
noted between the groups in terms of epidemiological, clinical or echocardio-
graphic characteristics. Patients with positive cardiac troponins were evaluated
for the presence of coronary lesions but none of them had significant disease.
After a 18 month mean follow-up, no adverse cardiac events were noted in
either groups. 
Conclusion: In high risk diabetic patients, the measurement of hs-cTnT
during DSE does not improve the sensitivity at least in those with negative
DSE tests
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Is there a differential expression of selected microRNAs depending on
stent’s type and length one month after coronary angioplasty?
Guillaume Bonnet (1), Esma Karkeni (2), Jacques Quilici (1), Thomas
Cuisset (1), Marie-Christine Alessi (2), Jean-François Landrier (2), Jean-
Louis Bonnet (1)
(1) CHU La Timone-APHM, Cardiologie interventionnelle, Marseille,
France – (2) NORT, UMR inserm 1062, inra 1260, Aix-Marseille Univer-
sité, Marseille, France
Stent thrombosis is a serious, although rare, complication of percuta-
neous coronary intervention (PCI). Some data from randomized trials indi-
cate a higher risk for drug- eluting stents (DES) thrombosis. Furthermore,
it has been shown that the most powerful histological predictor of stent
thrombosis was endothelial coverage and that reendothelialization was
delayed after implantation of first-generation DES compared with bare-
metal stents (BMS) as from the first month after PCI. We do not have yet
simple blood test biomarkers that could reflect the ongoing process of stent
reendothelialization. MicroRNAs are small, endogenous, noncoding RNAs,
easily detectable in plasma, involved in a variety of cellular processes via
suppression of specific target mRNAs and could be such biomarkers. Some
of them have been linked to endothelial function and reendothelialization in
animal or in vitro studies. We hypothesized that the expression of certain
microRNAs was informative of stent endothelialization. We therefore
sought beforehand to determine wether stent type and stent length could
influence the expression of candidate microRNAs in human peripheral
blood. Between July 2008 and December 2013, all patients who underwent
coronary angioplasty in our centre were asked to attend a systematic
consultation one month after revascularization for blood sampling. Sixty
patients with a single-vessel disease meeting over twenty clinical, biolo-
gical, echocardiographic and angiographic criteria were selected: 30 with a
BMS and 30 with a DES, with a balanced ratio of short (≤15mm) and long
(>15mm) stents in each group. Twenty eight microRNAs were chosen
based on a review of literature. Their expression was measured using qRT-
PCR in plasma samples collected at one month. Levels were normalized to
cel-miR-39 and compared between the two groups of patients. The results
are currently under analysis (table next page).
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Acute coronary syndrome complicated with left ventricular diastolic
dysfunction: what is the contribution of brain natriuretic peptid?
Leila Abid (1), Selma Charfeddine (1), Mouna Turki (2), Fatma Ayedi (2),
Samir Kammoun (1)
(1) CHU Hédi Chaker, Cardiologie, Sfax, Tunisie – (2) Habib Bourguiba
Hospital, Biochemistry laboratory, Sfax, Tunisie
Background: The utility of Brain Natriuretic Peptide (BNP) for detecting
leftventricular (LV) diastolic dysfunction in patients presenting an acute coro-
nary syndrome without heart failure symptoms is unclear. In this study, we
investigated the relation between BNP plasma levels and LV diastolic dysfunc-
tion in patients with postmyocardial infarction without systolic dysfunction.
Methods: We studied 81 patients (12 women, mean age 55±11.79) admitted
in our center for myocardial infarction with or without ST segment elevation.
Patients with heart failure symptoms or abnormal systolic function were
excluded. LV diastolic function was assessed with conventional Doppler, by
means of mitral inflow and with tissue Doppler echocardiography by means
of mitral annulus. The ratio of early diastolic transmitral E wave velocities to
tissue Doppler mitral annulus early diastolic E’ wave velocities (E/E’), was
used to detect LV filling pressures. Patients were divided in three groups
according to E/E’ ratios < 10 (group I), E/E’ ratios between 10 and 15 (group II)
and E/E’ ratios > 15 (group III).
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Results: The BNP blood levels were positively correlated significantly
with E/E’ ratio (p < 0.02). Patients with elevated LV end diastolic pressure
(LVEDP), defined as E/E’ > 15 (n = 27) had highest BNP (302±68 pg/ml)
levels. E/E’ 10 to 15 group (n = 24) had a mean BNP level of 136.4±27 pg/ml,
and those with E/E’ < 10 (n = 29) had 82±20 pg/ml. A BNP value of 107.8 pg/ml
had a sensitivity of 89%, a specificity of 61% for predicting E/E’ >15. The
area under the ROC curve for BNP to detect any diastolic dysfunction was
0.757. A BNP value of 72.7 pg/ml had a sensitivity of 82.2% and a specificity
of 66.7% for detecting a diastolic dysfunction. 
Conclusions: A rapid assay for BNP can detect the presence of diastolic
abnormalities on echocardiography. In patients with preserved systolic func-
tion post myocardial infarction, elevated BNP levels might help to reinforce
the diagnosis of LV diastolic dysfunction.
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Point-of-care genetic profiling in acute coronary syndrome 
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Background: Our aim was to examine the hypothesis that the sequential
use of the Verigene® rapid CYP2C19 test for genetic profiling and the Veri-
fynowTM bedside test for platelet function measurement in ACS patients may
improve P2Y12 inhibition. 
Methods and results: “Rapid” (CYP2C19*1/*1 or CYP2C19*17 carriers,
n=211) and “slow” metabolizers (CYP2C19*2 carriers, n=58) were first put
on clopidogrel and prasugrel MD for ≥2 weeks, respectively. Patients with
low inhibition >80% on prasugrel or high inhibition <30% on clopidogrel
were then switched to clopidogrel and prasugrel, respectively. Our objectives
were to demonstrate that the proportion of “rapid” metabolizers on 75mg MD
of clopidogrel within 30%-80% of P2Y12 inhibition is non-inferior to “slow”
metabolizers on prasugrel 10mg MD and (ii) to evaluate the same end-point
after switching drugs. The proportion of “rapid” and “slow” metabolizers
within 30%-80% of P2Y12 inhibition was 58.5% and 44.8%, respectively, an
absolute difference of +13.6% (95% CI (confidence interval), –0.8% to
28.1%) with a non-inferiority margin greater than the predefined margin of
–10%. Among patients out of target, all but one “slow” metabolizers displayed
low-on prasugrel platelet reactivity while the majority of “rapid” metabolizers
(70%) displayed high-on clopidogrel platelet reactivity. After switching, the
proportion of patients within 30%-80% of P2Y12 inhibition was 74.4% and
65.5% in “rapid” and “slow” metabolizers, respectively (+8.9%, 95% CI –4.7%
to 22.5%).
Conclusions: This study demonstrates a loose relationship between geno-
type and platelet function phenotype approaches but that they are complemen-
tary to select prasugrel or clopidogrel MD in stented ACS patients. 
Abstract 0109 – Table: Patients' baseline characteristics
Patients’baseline characteristics
BMS (n=30) DES (n=300) p
Sex, M/F 30/0 30/0 1
Age, y 52,03±6,35 50,2±8,45 0,34
Body mass index*, kg/m2 25,79±2,56 25,00±2,97 0,28
Hypertension, % 16,66 1,66 1
Dyslipidemia, % 33,33 33,33 1
Diabetes mellitus, % 0 0 1
Family history, % 26,66 6,66 0,07
Cigarette smoking, % 73,33 60 0,41
Previous CAD, Stroke, PAOD, % 0 0 1
Indication of coronary 
angiography
AMI (STEMI/NSTEMI, % 86,66 76,66 0,5
UA, % 13,33 16,66 1
SCAD, % 0 6,66 0,49
Time interval between PCI and 
blood sampling, d
39,16±7,68 38,73±6,76 0,81
Stent length, mm 16,3±4,24 17,56±5,71 0,33
LVEF, % 58,66±7,30 61,13±6,18 0,16
Drug therapies*
Statin, % 100 100 1
ASA, % 100 100 1
Second anti-platelet drug
Clopidogrel, % 46,66 43,33 1
Prasugrel, % 53,33 50 1
Ticagrelor, % 0 6,66 0,49
β-blocker, % 85,71 (n=28) 60 (n=25) 0,059
ACE inhibitor, % 89,28 (n=28) 80,76 (n=26) 0,46
AT-RB, % 0 (n=28) 0 (n=26) 1
OAC, % 0 0 1
Blood tests*
LDL cholesterol, g/L 0,75±0,18 0,68±0,19 0,19
HDL cholesterol, g/L 0,39±0,10 0,43±0,11 0,19
Triglyceride, g/L 0,96±0,32 0,93±0,29 0,72
Hemoblogin, g/dl 14,34±0,97 14,4±0,83 0,82
Platelets, G/L 242,93±55,90 239,56±49,61 0,8
Serum creatinine, μmol/L 88,6±14,60 82,73±14,59 0,12
CRP, mg/L 2,07±2,02 1,39±1,30 0,12
Fasted glycaemia, g/L 0,97±0,11 1,01±0,09 0,14
HbA1c, % 5,74±0,39 5,73±0,40 0,92
Continuous variables are presented as sample mean and standard deviation. 
P-values reflect comparisons between patients with a BMS and patients with 
DES and are derived from Student’s t-tests for continuous variables whereas 
qualitative data were compared with Fisher’s exact test.
The characteristics marked with an asterisk were collected on the same day 
that blood was sampled (one month after PCI).
